Abstract
Development of pancreatic cancers is clinically so silent in general that at the time of diagnosis, the vast majority of cases are incurable with a very poor prognosis. Therefore, effective preventive approaches against this aggressive disease are urgently required. Experimentally, carcinogenesis process is assumed to consist of at least two stages named initiation and promotion. Using a two-stage model of hamster pancreatic carcinogenesis, we have reported stage-specific inhibitory effects by a number of potent cancer chemopreventive agents. Among them, phenethyl isothiocyanate (PEITC), a constituent of cruciferous vegetables, remarkably blocked the initiation phase of pancreatic as well as lung carcinogenesis in hamsters initiated with N-nitrosobis(2-oxopropyl)amine (BOP). However, PEITC failed to affect both pancreatic and lung carcinogenesis when given during the post-initiation (promotion) phase of carcinogenesis. In contrast, our recent study clearly demonstrated that a cyclooxygenase (COX)-2 inhibitor substantially protects against BOP-induced pancreatic tumors in hamsters in line with decrease in cell proliferative activity of pancreatic ducts when given in the post-initiation phase. Interestingly, trypsin inhibitors inhibited both initiation and post-initiation phases of BOP-induced pancreatic carcinogenesis although they are known to induce hyperplastic acinar lesions in the rat pancreas. Taken together with these data, our review is aimed at looking over mechanistic insights into potent chemopreventive agents against pancreatic cancer.
Keywords: chemopreventiveagents, pancreatic cancer, n-nitrosobis(2-oxopropyl)amine, phenethyl isothiocyanate
Current Cancer Drug Targets
Title: Potent Chemopreventive Agents Against Pancreatic Cancer
Volume: 4 Issue: 4
Author(s): Akiyoshi Nishikawa, Fumio Furukawa, In-Seon Lee, Takuji Tanaka and Masao Hirose
Affiliation:
Keywords: chemopreventiveagents, pancreatic cancer, n-nitrosobis(2-oxopropyl)amine, phenethyl isothiocyanate
Abstract: Development of pancreatic cancers is clinically so silent in general that at the time of diagnosis, the vast majority of cases are incurable with a very poor prognosis. Therefore, effective preventive approaches against this aggressive disease are urgently required. Experimentally, carcinogenesis process is assumed to consist of at least two stages named initiation and promotion. Using a two-stage model of hamster pancreatic carcinogenesis, we have reported stage-specific inhibitory effects by a number of potent cancer chemopreventive agents. Among them, phenethyl isothiocyanate (PEITC), a constituent of cruciferous vegetables, remarkably blocked the initiation phase of pancreatic as well as lung carcinogenesis in hamsters initiated with N-nitrosobis(2-oxopropyl)amine (BOP). However, PEITC failed to affect both pancreatic and lung carcinogenesis when given during the post-initiation (promotion) phase of carcinogenesis. In contrast, our recent study clearly demonstrated that a cyclooxygenase (COX)-2 inhibitor substantially protects against BOP-induced pancreatic tumors in hamsters in line with decrease in cell proliferative activity of pancreatic ducts when given in the post-initiation phase. Interestingly, trypsin inhibitors inhibited both initiation and post-initiation phases of BOP-induced pancreatic carcinogenesis although they are known to induce hyperplastic acinar lesions in the rat pancreas. Taken together with these data, our review is aimed at looking over mechanistic insights into potent chemopreventive agents against pancreatic cancer.
Export Options
About this article
Cite this article as:
Nishikawa Akiyoshi, Furukawa Fumio, Lee In-Seon, Tanaka Takuji and Hirose Masao, Potent Chemopreventive Agents Against Pancreatic Cancer, Current Cancer Drug Targets 2004; 4 (4) . https://dx.doi.org/10.2174/1568009043332970
DOI https://dx.doi.org/10.2174/1568009043332970 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Bioactive Polysaccharides From Natural Resources For Cancer Therapy
Bioactive polysaccharides from natural resources exhibit diverse therapeutic properties including anticancer, antioxidant, antidiabetic, immunostimulatory activity, and promotion of wound healing. In the past decades, most studies focused on the extraction and identification of polysaccharides, as well as their biological activities. A large number of bioactive polysaccharides with different structural features ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Innovative Drug Research Propelling a New Era of Precision Oncology
Drug-oncology research is leading a new era of precision medicine, becoming a frontier hotspot in cancer treatment. Advancements in molecular biology, genomics, and medicinal chemistry have driven revolutionary changes in cancer cognition and treatment strategies. Gene-targeted drugs provide more precise treatments, improving survival rates for certain cancers. Network pharmacology offers ...read more
Novel Targets in Cancer Immunotherapy
Cancer immunotherapy, particularly immune checkpoint inhibitors (ICIs), has greatly revolutionized therapeutic strategies in the field of cancer. Current targets of FDA-approved ICIs include CTLA-4, PD-1/PDl-1, and LAG-3. However, the prognosis of cancer patients, especially with solid tumors, remains unfavorable due to the intrinsic and acquired resistance. For the past decades, ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety Gene Therapy: Optimising DNA Delivery to the Nucleus
Current Drug Targets Breast Cancer: Understanding Sensitivity and Resistance to Chemotherapy and Targeted Therapies to Aid in Personalised Medicine
Current Cancer Drug Targets Pyruvate Kinase M2: Regulatory Circuits and Potential for Therapeutic Intervention
Current Pharmaceutical Design microRNAs, Gap Junctional Intercellular Communication and Mesenchymal Stem Cells in Breast Cancer Metastasis
Current Cancer Therapy Reviews Seeking the 5th Base of DNA Using Chromatographic Methods of Analysis
Current Organic Chemistry Revising Skin Cancers by Means of Epigenetic Markers
Recent Patents on Biomarkers Management of Inflammatory Bowel Disease Patients with a Cancer History
Current Drug Targets The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design p53 as the Focus of Gene Therapy: Past, Present and Future
Current Drug Targets Chlorophylls and their Derivatives Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Nano-Enabled Drug Delivery in Cancer Therapy: Literature Analysis Using the MeSH System
Pharmaceutical Nanotechnology Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far
Recent Patents on Anti-Cancer Drug Discovery Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Lung Cancer Stem Cells: An Epigenetic Perspective
Current Cancer Drug Targets Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry A Comprehensive Review on Nanotechnology-Based Innovations in Topical Drug Delivery for the Treatment of Skin Cancer
Current Pharmaceutical Design Medical Treatment of Malignancy-Associated Hypercalcemia
Current Medicinal Chemistry Molecular Targeting of Drug Delivery Systems to Cancer
Current Drug Targets Inflammatory Mediators Hold the Key to Dendritic Cell Suppression and Tumor Progression
Current Medicinal Chemistry